CORE E: NOVEL TARGET DISCOVERY AND ASSAY

核心 E：新靶标发现和测定

• 批准号: 8913137
• 负责人: Julian P Whitelegge
• 金额: $ 21.67万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-05-01 至 2016-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8913137
• 关键词: Address; Animal Experiments; Binding; Bioinformatics; Biological; Biological Assay; Biological Markers; Biological Process; Biology; Cells; Clinic; Clinical; Communication; Communities; Complement; Complications of Diabetes Mellitus; Computer software; Consult; Continuing Education; Data; Databases; Development; Diabetes Mellitus; Enzyme-Linked Immunosorbent Assay; Epigenetic Process; Foundations; Funding; Genetic; Genomics; Goals; Homologous Gene; Human; Human Genetics; Individual; Inflammatory; Institutes; Insulin; Insulin Resistance; Insulin-Like Growth-Factor-Binding Proteins; Ions; Knockout Mice; Label; Lead; Leadership; Learning; Length; Liquid Chromatography; Mass Spectrum Analysis; Measurement; Measures; Metabolic; Metabolism; Mission; Molecular; Monitor; Mus; Obesity; Outcome; Patients; Peptides; Performance; Physiology; Post-Translational Protein Processing; Prevention; Protein Analysis; Protein Isoforms; Proteins; Proteomics; Qualifying; Quality Control; Reaction; Reagent; Relative (related person); Research; Research Personnel; Resolution; Resources; Sampling; Services; Signal Transduction; Stable Isotope Labeling; Statistical Data Interpretation; Strategic Planning; Structure; System; Testing; Transgenic Organisms; Translating; Translations; Validation; assay development; biological systems; clinical assay development; clinically relevant; combat; cost effective; data mining; design; empowered; experience; high throughput screening; humanin; improved; interest; mass spectrometer; meetings; member; nano; novel; novel therapeutics; outreach; polyclonal antibody; research study; scaffold; statistics; synthetic peptide; tandem mass spectrometry

The Novel Target Discovery and Assay Development Core (NTDAC) will provide investigators at UCLA, UCSD, the Salk Institute and Cedars-Sinai with consultancy and a suite of state-of-the-art molecular measurements not available from other national resources. The new NTDAC core assembles a comprehensive and highly specialized core with expertize in biological mass spectrometry and proteomics (Julian Whitelegge, Director) and ELISA assay development (Pinchas Cohen, Co-Director). Strengths of this biomedical core include the extensive expertise ofthe core leadership in diabetes research, wide experience in protein and peptide analysis, access to bioinformatics resources, and the collegial outreach of NTDAC leadership to DRC investigators to assist in the strategic planning and execution of studies relevant to the DRC mission. Core goals include: 1) provide an accessible user interface toward meeting objectives in a timely, cost effective, and integrated manner individualized to the specific needs of each DRC investigator, 2) provide discovery mass spectrometry services with appropriate bioinformafics for sensitive, accurate measurements with quality control, 3) provide biomarker qualificafion, immunocapture and top-down mass spectrometry for qualification of lead proteins and peptides with respect to biological function, 4) provide assay construction for novel peptides and proteins, and optimization of reliable assays toward the clinic, 5) provide ELISA services for novel assays for development of new clinical assays for better pafient outcomes in diabetes. The collective and complementary expertise of the core leadership is outstanding and provides DRC invesfigators with an opportunity to explore and implement experimental strategies that rely upon direct analysis of proteins and peptides. The new NTDAC core provides discovery proteomics and peptidomics, alongside the lipidomics component that has been introduced into the MMPC (core B). The core will synergize with the other DRC cores through many favorable interactions including identification of interaction partners (core A), integrafion with metabolism and physiology studies (core B) and enhanced bioinformatics resources related to the genomics and genetics cores (C & D). Collectively, our ability to study the proteins and peptides of insulin action, substrate metabolism, and inflammatory signaling will drive the UCSD-UCLA DRC fonfl/ard in discovery of critical biological molecules involved in the pathobiology of obesity and insulin resistance, and provide a foundation for the development of novel therapeutic strategies to combat diabetes and diabetes complications.

新靶点发现和检测开发核心（NTDAC）将为加州大学洛杉矶分校的研究人员提供， 加州大学圣地亚哥分校，索尔克研究所和雪松西奈与咨询和一套国家的最先进的分子 其他国家资源无法提供的测量数据。新的NTDAC核心组装了一个 全面和高度专业化的核心，在生物质谱和蛋白质组学方面具有专业知识 （Julian Whitelegge，总监）和ELISA测定开发（Pinchas Cohen，联席总监）。这个的优点 生物医学核心包括糖尿病研究核心领导层的广泛专业知识， 在蛋白质和肽分析，获得生物信息学资源，以及NTDAC的合议外展 领导DRC调查人员，协助战略规划和执行与 刚果民主共和国使命。核心目标包括：1）提供一个可访问的用户界面， 及时、经济、综合的方式，满足每位DRC研究者的具体需求，2） 为发现质谱服务提供适当的生物信息学， 3）提供生物标志物定性、免疫捕获和自上而下的质量 用于鉴定先导蛋白质和肽生物学功能光谱法，4）提供 新型肽和蛋白质的测定构建，以及面向临床的可靠测定的优化，5） 为开发新的临床检测方法提供ELISA服务，以获得更好的疗效 在糖尿病中。核心领导层的集体和互补专长是杰出的， DRC投资者有机会探索和实施依赖于直接 蛋白质和肽的分析。新的NTDAC核心提供发现蛋白质组学和肽组学， 与已引入MMPC的脂质组学组分（核心B）一起。芯会 通过许多有利的相互作用与其他DRC核心协同，包括识别相互作用 合作伙伴（核心A），与代谢和生理学研究的整合（核心B）和增强的生物信息学 与基因组学和遗传学核心（C & D）相关的资源。总的来说，我们研究蛋白质的能力 胰岛素作用肽、底物代谢和炎症信号将驱动UCSD-UCLA DRC fonfl/ard发现了与肥胖和胰岛素的病理生物学有关的关键生物分子 耐药性，并为开发新的治疗策略以对抗糖尿病提供基础 和糖尿病并发症。